期刊
CANCER IMMUNOLOGY IMMUNOTHERAPY
卷 58, 期 11, 页码 1803-1809出版社
SPRINGER
DOI: 10.1007/s00262-009-0691-x
关键词
Immunotherapy; Survivin; Peptide vaccination; Urothelial cancer
资金
- Ministry of Health, Labor and Welfare
- Ministry of Education, Culture, Sports, Science and Technology of Japan [17390441]
- Stiftelsen Japanese-Swedish Research Foundation
- Gotaro Sugawara Research Fund for Urological Diseases
- Grants-in-Aid for Scientific Research [21249025, 17390441, 21590401] Funding Source: KAKEN
Survivin, a member of the inhibitor of apoptosis protein family, is expressed in many malignant tumors including urothelial cancer but is hardly detectable in normal, differentiated adult tissues. Previously we reported CD8-positive cytotoxic T-lymphocytes (CTLs) were successfully induced by stimulation with survivin-2B80-88 peptide in vitro. We started a phase I clinical study of survivin-2B80-88 peptide vaccination for advanced urothelial cancer patients to assess the safety and efficacy of this vaccination. Nine patients were received vaccination and were evaluated for immunological evaluation, adverse events, and clinical responses. A total of 46 vaccinations were carried out. There was no severe adverse event. HLA-A24/survivin-2B80-88 peptide tetramer analysis revealed a significant increase in the peptide-specific CTL frequency after the vaccination in five patients. Slight reduction of the tumor volume was observed in one patient. Survivin-2B80-88 peptide-based vaccination is safe and should be further considered for potential immune and clinical efficacy in urothelial cancer patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据